Eli, a health technology company, raises $12M in Series A funding led by BDC Capital’s Thrive Venture Fund.
The funding will support the launch of the Hormometer™, the world’s first real-time hormone monitoring system, addressing a gap in personalized health.
Traditional testing methods for hormones offer only a single snapshot in time, leading to underdiagnosed health crises.
1 in 3 adults show signs of cortisol dysregulation, and 60% of adults experience symptoms related to hormone imbalances.
The Hormometer by Eli tracks hormones instantly using saliva and a smartphone, providing results in minutes without laboratory testing.
Eli's Hormometer offers real-time hormone monitoring, giving users immediate insights into their biology.
The Hormometer is the result of years of R&D, featuring biochemistry for microfluidics, AI for signal interpretation, and customized hardware.
Eli aims to scale production, expand audience access, and unlock more biomarkers like cortisol and progesterone with the new funding.
The Hormometer will enable individuals to understand their bodies' current state and take informed actions based on the real-time data.